Canadian Researcher Guide · 2026
CJC-1295 (Mod GRF 1-29) in Canada: Benefits, Research & Where to Buy
CJC-1295 is one of the most talked-about GHRH analogs among researchers studying peptides in Canada — but it also comes with one of the most confusing naming situations in the whole peptide space. Depending on where you look, the same compound might be called CJC-1295, Mod GRF 1-29, Modified GRF (1-29), or CJC-1295 without DAC. They all refer to the same peptide. What’s actually different is CJC-1295 with DAC — and that distinction has real consequences for how the compound behaves in research.
Clearing Up the Name Confusion First
This is worth addressing before anything else, because it trips up even experienced researchers. Here are the facts:
Mod GRF 1-29, CJC-1295 without DAC, and Modified GRF (1-29) are all the same compound. It’s a 29-amino-acid synthetic analog of GHRH with four amino acid substitutions that make it more resistant to enzymatic breakdown than native GHRH. Half-life is approximately 30 minutes. It fires a clean, short GH pulse and clears the system — closely mimicking how the body naturally releases GH.
CJC-1295 with DAC is a different compound. DAC stands for Drug Affinity Complex — it’s a chemical modification added to the C-terminus that allows the peptide to bind to albumin in the bloodstream. This dramatically extends its half-life to 6–8 days, meaning a single injection keeps stimulating GH release continuously for almost a week. The research implications of that difference are significant, and not always in a good way — more on that below.
Wikipedia explicitly notes that CJC-1295 and Modified GRF (1-29) are incorrectly equated in several scientific papers, which is part of why the confusion persists. The product Boss Peptides sells is the no-DAC version — Mod GRF 1-29 — which preserves natural pulsatile GH release and is the version used in nearly all GHRH + GHRP combination research.
What Is Mod GRF 1-29?
Mod GRF 1-29 is a synthetic analog of the first 29 amino acids of Growth Hormone-Releasing Hormone (GHRH). The naturally occurring GHRH peptide contains 44 amino acids, but the first 29 are all that’s needed to fully activate the GHRH receptor on pituitary somatotroph cells. Native GRF (1-29) — called Sermorelin in its pharmaceutical form — has a half-life of only a few minutes because it’s rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) and other plasma enzymes.
Mod GRF 1-29 solves this with four strategic amino acid substitutions: D-alanine at position 2 (which blocks DPP-IV cleavage), glutamine at position 8, alanine at position 15, and leucine at position 27. Each substitution targets a specific enzymatic cleavage site. The result is a peptide with the same GHRH receptor affinity as the native sequence but roughly 10–15x longer half-life — around 30 minutes, compared to 2–3 minutes for native GHRH. This is long enough to trigger a meaningful GH pulse while still clearing quickly enough to preserve the body’s natural pulsatile GH rhythm.
In terms of GH pulse amplitude, Mod GRF 1-29 is stronger than Sermorelin per dose. Research has shown it produces approximately 70–107% increases in mean 12-hour GH release from pituitary somatotrophs compared to baseline — a substantial effect through the GHRH receptor pathway alone.
How Mod GRF 1-29 Works
When Mod GRF 1-29 binds to GHRH receptors on pituitary somatotroph cells, it activates the Gs signalling pathway — stimulating adenylate cyclase, raising intracellular cyclic AMP (cAMP), and activating PKA-linked phosphorylation cascades. This triggers both GH synthesis (upregulating GH mRNA and pituitary GH content over time) and immediate GH secretion in a pulse.
The downstream effects run through two channels. GH acts directly on tissues to promote lipolysis (fat breakdown) and protein synthesis. It also signals the liver to produce IGF-1, which mediates most of GH’s anabolic tissue-level effects: muscle fiber hypertrophy, bone remodeling, collagen synthesis, and cellular repair. Because Mod GRF 1-29 works through the GHRH receptor — not the ghrelin receptor — it doesn’t activate appetite centers or raise cortisol or prolactin. Its hormonal footprint is clean.
DAC vs. No DAC: Why the Distinction Matters for Research
This comparison deserves its own section because the difference in research utility is significant — and the peptide community often misses the tradeoff.
CJC-1295 with DAC (half-life: 6–8 days)
The DAC modification allows the peptide to covalently bind to the cysteine-34 position on serum albumin after injection. This protects it from clearance and keeps it continuously active for nearly a week from a single injection. The Teichman et al. (2006) human trial in the Journal of Clinical Endocrinology & Metabolism found that a single injection of CJC-1295 (with DAC) raised mean plasma GH concentrations by 2–10 fold for 6 days or more, and IGF-1 concentrations by 1.5–3 fold for 9–11 days. With multiple doses, IGF-1 remained elevated for up to 28 days.
That sounds impressive — but the problem is that continuous GHRH stimulation disrupts the natural pulsatile pattern of GH release. GH’s physiological effects depend not just on its level but on its pattern: the liver, muscle, and fat cells respond differently to pulsatile GH vs. a sustained tonic elevation. Continuous stimulation also risks downregulating GHRH receptors over time. And because it keeps GH elevated non-stop, it cannot synergize properly with GHRPs like Ipamorelin, which are designed to amplify a discrete GH pulse — there’s no distinct pulse to amplify when GH is already chronically elevated.
CJC-1295 with DAC was also the version involved in a Phase II clinical trial that was discontinued after one subject death — the attending physician believed the cause was unrelated to the peptide (asymptomatic coronary artery disease with plaque rupture), but the trial was terminated as a precaution regardless.
Mod GRF 1-29 / CJC-1295 without DAC (half-life: ~30 minutes)
The no-DAC version fires a defined GH pulse and clears within 30–60 minutes. GH levels spike, peak, and return to baseline — exactly what happens naturally. This preserves receptor sensitivity, maintains the physiological pulsatile pattern, and critically, creates a defined window for GHRP co-administration to amplify.
A second landmark study by Ionescu and Frohman (2006) in the same journal tested whether CJC-1295 (with DAC) disrupted natural GH pulsatility. The result was nuanced: GH pulsatility was preserved in terms of pulse frequency and amplitude, but basal (trough) GH levels were raised 7.5-fold, and mean GH levels increased 46%. IGF-1 rose 45%. This showed the DAC version creates a floor of chronically elevated GH rather than amplifying discrete pulses — a fundamentally different physiological state than what Mod GRF 1-29 produces.
What the Research Shows: Benefits by Area
Most of the human data on GHRH analogs comes from CJC-1295 with DAC studies (since it was the version in clinical trials), but the downstream effects — driven by GH and IGF-1 elevation — apply to Mod GRF 1-29 as well, since both compounds activate the same GHRH receptor and produce the same hormonal cascade. Additional data comes from Mod GRF 1-29 specific studies and research on GHRH analogs more broadly.
GH and IGF-1 Elevation
The Teichman et al. (2006) trial — two randomized, placebo-controlled, double-blind studies in healthy adults aged 21–61 — is the most cited human data on this peptide class. A single subcutaneous injection raised GH by 2–10 fold for 6+ days and IGF-1 by 1.5–3 fold for 9–11 days. No serious adverse reactions were reported. The study was well-tolerated, particularly at doses of 30–60 mcg/kg. Crucially, a follow-up proteomic analysis (Sackmann-Sala et al., 2009) found that the CJC-1295-driven IGF-1 elevation correlated with measurable decreases in fat mass and increases in lean mass in the subjects — a direct body composition signal from the GH axis activation.
Lean Body Mass and Muscle Preservation
GH and IGF-1 are both potent drivers of muscle protein synthesis. IGF-1 binds to receptors on muscle fibers, activating the PI3K/Akt/mTOR pathway that drives muscle hypertrophy and inhibits protein breakdown. A 4-month study using a Mod GRF analog found male subjects gained an average of 1.26 kg of lean body mass, with secondary improvements in skin thickness and insulin sensitivity. The mechanism runs through increased satellite cell activation — the stem cells responsible for muscle repair and growth — and upregulated protein synthesis at the ribosomal level.
Fat Metabolism and Body Composition
GH promotes lipolysis directly by activating hormone-sensitive lipase in fat cells, preferentially targeting visceral adipose tissue. The Sackmann-Sala proteomic study confirmed that GHRH analog-driven GH/IGF-1 elevation was associated with decreased fat mass independent of IGF-1 levels alone, suggesting direct GH-mediated fat breakdown rather than a purely IGF-1 driven effect. When Mod GRF 1-29 is paired with Ipamorelin — amplifying the GH pulse through a second receptor pathway — the lipolytic effect is correspondingly larger.
Bone Density and Collagen Synthesis
IGF-1 stimulates osteoblast proliferation and bone matrix collagen synthesis. GHRH analog research in GH-deficient animals has shown normalization of bone mineral density and femur/tibia length with treatment. At the tissue level, GH and IGF-1 increase collagen deposition in both bone matrix and connective tissues — tendons, ligaments, and skin — which is why GHRH peptide research intersects with orthopaedics and wound healing. The Teichman human trial also noted increases in IGFBP-3 alongside IGF-1 elevation, which modulates IGF-1 bioavailability and bone tissue signaling.
Sleep Quality
The majority of natural GH release occurs during the first few hours of slow-wave sleep. Because Mod GRF 1-29 triggers a GH pulse that peaks around 30–40 minutes post-injection and then clears, timing an injection before bed aligns the peptide-driven GH pulse with the body’s natural nocturnal GH window. Multiple GHRH research protocols and clinical providers using these peptides have documented improvements in slow-wave sleep depth and sleep onset, consistent with studies showing GHRH administration increases deep sleep in both young and older adults.
Cardiovascular and Metabolic Effects
Preliminary research in murine models suggested that Mod GRF 1-29 and other GHRH derivative analogs may support cardiac function, particularly following ischemic events, through VPAC receptor interactions on smooth muscle. The Sackmann-Sala proteomic study also found changes in apolipoprotein A1 and transthyretin levels after CJC-1295 treatment — proteins involved in lipid transport and thyroid hormone metabolism respectively — suggesting broader metabolic effects beyond the GH/IGF-1 axis that warrant further research.
The Boss Peptides CJC-1295 Lineup
Boss Peptides carries two formulations built around Mod GRF 1-29. Here’s the research rationale for each.
Mod GRF 1-29 / CJC-1295 No DAC (5mg) — The Standalone GHRH Analog
The Mod GRF 1-29 / CJC-1295 No DAC (5mg) is the standalone compound for researchers who want to study GHRH receptor activation in isolation, or who are building a custom stack and want to pair it with a GHRP of their choice. At 5mg per vial, it provides a solid supply for multi-week research protocols at standard doses (100–200 mcg per injection).
This is also the right choice for researchers who want the cleanest possible GHRH signal without the additional variables introduced by a pre-blended combination. Because Mod GRF 1-29 has a defined 30-minute half-life and produces a discrete GH pulse, it’s ideal for circadian rhythm studies, receptor sensitivity research, and any protocol where you need precise control over GH pulse timing.
The most common pairing in research is with Ipamorelin — injected simultaneously, the two peptides hit GHRH receptors and ghrelin receptors at the same time, producing a synergistic GH pulse that’s significantly larger than either compound alone. This combination is so well-established that it’s been described as the benchmark GHRH + GHRP stack in the peptide research community.
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) — Triple-Pathway Coverage
The Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) adds Tesamorelin to the Mod GRF 1-29 + Ipamorelin stack — creating a three-peptide GH secretagogue combination that covers the GH axis through three distinct but complementary mechanisms simultaneously.
Tesamorelin is a 44-amino-acid GHRH analog — the only one with FDA approval, used clinically for HIV-associated lipodystrophy. It brings a level of clinical validation to the stack that most research peptides don’t have. Its primary documented effect in human trials is visceral fat reduction: the REDUCE trial and related studies found Tesamorelin produced a 4.7% absolute decrease in hepatic fat (a 37% relative reduction), slowed liver fibrosis progression (10.5% progression vs. 37.5% in placebo), and 35% of subjects achieved hepatic fat fraction below 5% vs. just 4% in placebo.
In this triple blend, Tesamorelin and Mod GRF 1-29 both activate the GHRH receptor — but they are structurally distinct peptides with different half-lives and degradation profiles, meaning they may activate the receptor in slightly different temporal patterns and produce a combined GHRH signal larger than either alone. Ipamorelin then amplifies the resultant GH pulse through the ghrelin receptor. Research suggests the Tesamorelin + Mod GRF combination produces a synergistic increase in GH levels surpassing either peptide in isolation.
The result is a stack that covers visceral fat reduction (Tesamorelin), amplified pulsatile GH release (Mod GRF 1-29), and clean ghrelin receptor activation without cortisol or prolactin elevation (Ipamorelin) — all in a single pre-blended vial. For researchers studying comprehensive GH axis modulation or the intersection of GH secretagogues and metabolic function, this is the most thorough single-vial protocol available.
Safety Profile
The safety profile of Mod GRF 1-29 is well-characterized through both direct research and data on related GHRH analogs. In the Teichman et al. (2006) human trials — the most rigorous human data on this peptide class — no serious adverse reactions were reported across two randomized, double-blind, placebo-controlled studies. The compound was well-tolerated at doses of 30–60 mcg/kg in healthy adults aged 21–61.
The most commonly reported side effects in research settings are mild and transient: injection site redness or irritation, brief flushing, headache, and occasional water retention. Because Mod GRF 1-29 works through the GHRH receptor rather than the ghrelin receptor, it doesn’t cause the appetite stimulation seen with GHRP-6, and it doesn’t elevate cortisol or prolactin.
One practical note specific to Mod GRF 1-29: because it has a short half-life and produces a defined pulse, dosing errors or unexpected side effects are easier to manage than with CJC-1295 with DAC, which stays active for a week and can’t be quickly cleared if a problem arises.
Dosing: Reference Points from the Research
No official dosing guidelines exist for Mod GRF 1-29 outside of clinical GHRH research. In research and clinical optimization contexts, 100–200 mcg per injection is the most commonly referenced range. Because the half-life is approximately 30 minutes, most protocols inject once or twice daily — before bed to align with the nocturnal GH peak, and optionally post-exercise when pituitary GH responsiveness is elevated.
When stacking with Ipamorelin, both peptides are typically injected simultaneously. The rationale is that Mod GRF 1-29 primes the GHRH receptor while Ipamorelin activates the ghrelin receptor in parallel — the combined signal produces a single, amplified GH pulse that peaks around 30–40 minutes post-injection and then clears normally. Fasting for 2–3 hours before injection is recommended, since elevated insulin from recent food intake suppresses GH release and reduces the effectiveness of any GH secretagogue.
For help calculating reconstitution volumes and syringe unit calculations for any vial size, the Peptide Dosage Calculator on the Boss Peptides site handles the math.
Regulatory Status in Canada
Mod GRF 1-29 / CJC-1295 is not approved by Health Canada for human therapeutic use. In Canada, it is sold legally as a research chemical. CJC-1295 with DAC reached Phase II clinical trials in the US and Canada but was discontinued. The no-DAC version (Mod GRF 1-29) has not been through clinical trials independently, but shares its mechanism and GHRH receptor pharmacology with Sermorelin, which has an established pharmaceutical history.
Where to Buy CJC-1295 in Canada
For researchers looking to buy CJC-1295 in Canada, the sourcing standards are identical to any injectable research peptide: HPLC purity of 98% or higher, mass spectrometry identity confirmation, sterility testing, and a certificate of analysis from an independent third-party lab. Given that Mod GRF 1-29 is a short peptide that degrades quickly with improper storage or synthesis, purity documentation is especially important — a degraded batch won’t produce reliable research results.
Boss Peptides ships from a Canadian facility with COAs published on every product page. For researchers looking to buy CJC-1295 in Ontario, orders typically arrive next business day. Both CJC-1295 formulations are below:
- 1 Mod GRF 1-29 / CJC-1295 No DAC (5mg) — standalone GHRH receptor agonist for pulsatile GH research or custom stacking with a GHRP of your choice.
- 2 Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) — triple-pathway GH stack combining dual GHRH receptor activation with Ipamorelin’s clean ghrelin receptor signal.
The Bottom Line
Mod GRF 1-29 — sold under the CJC-1295 no DAC name — is the GHRH analog of choice for pulsatile GH research. Its structural modifications give it meaningfully better stability than native GHRH or Sermorelin, it produces a stronger GH pulse per dose, and its short half-life preserves the natural GH rhythm that makes GHRH + GHRP combination research possible.
The naming confusion with CJC-1295 with DAC is real and worth understanding before you buy. They are different compounds with different half-lives, different GH release patterns, and different research applications. The no-DAC version is what you want for pulsatile protocols, GHRP stacking, and physiological GH modulation research.
For researchers in Canada looking to buy CJC-1295 in Ontario or anywhere across the country, Boss Peptides provides third-party tested Mod GRF 1-29 with documentation on every batch — standalone or as part of the triple-blend stack with Tesamorelin and Ipamorelin.
Shop Mod GRF 1-29 / CJC-1295 No DAC →